The safety and efficacy of Isa-VRd in patients with transplant-ineligible NDMM

IMROZ: Isa-VRd vs VRd for transplant-ineligible newly diagnosed multiple myelomaПодробнее

Isatuximab + Len/Dex/Bortezomib vs IsaRd in Newly Diagnosed Transplant Ineligible Multiple MyelomaПодробнее

Isa-VRd vs VRd for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (IMROZ)Подробнее

ASCO 2024 Top 5 SARCLISA Isatuximab + VRd Phase 3 IMROZ Multiple Myeloma QuestionsПодробнее

Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and dexamethasone combined ther...Подробнее